CVS pushes into making cheaper versions of complex drugs with new discount Humira

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

from Health and Science https://ift.tt/Bf8xJiM
https://ift.tt/D8zTMRC
https://ift.tt/cY1Ond4